Introduction
Atrial natriuretic peptide is a 28 amino acid hormone which is involved in the regulation of sodium and water homeostasis. It is released from the atrial cardiomyocytes in response to stretch [1] and is broken down in the circulation through the action of the neutral endopeptidase EC 3.4.24.11 [2] [3] [4] . Exogenous administration of atrial natriuretic peptide causes a natriuresis [5, 6] , vasodilatation [7, 8] , and reduction in renin and aldosterone plasma concentrations [9] . These properties therefore make the elevation of atrial natriuretic peptide a potentially valuable new approach in the therapy of chronic heart failure.
Candoxatril is an orally active inhibitor of EC 3.4.24.11 and is well tolerated in man [10] [11] [12] [13] [14] . It causes an elevation in plasma atrial natriuretic peptide concentrations [4, 12, 15] and thereby induces a natriuresis [12, 15, 16] , a diuresis [12, 15] , and a reduction in plasma renin activity and aldosterone concentrations [4, 12] . In patients with chronic heart failure, these effects are associated with improvements in haemodynamic parameters, such as reduced capillary wedge pressure and increased cardiac index [12] . The benefits of angiotensin-converting enzyme (ACE) inhibition on mortality and morbidity in patients with chronic heart failure are well established [17] [18] [19] [20] [21] . Early clinical studies have demonstrated an improvement in the clinical status and exercise times in response to enalapril [22, 23] . A preliminary study has shown equivalent improvements in the exercise times in patients treated with either candoxatril or captopril [24] . Combined neutral endopeptidase and ACE inhibitor therapy, in patients with congestive heart failure, has the theoretical potential to act synergistically to suppress the deleterious neuroendocrine activation of the reninangiotensin system [25] . However, it is unknown whether combined therapy provides additional clinical improvement in these patients when compared to ACE inhibitor therapy alone.
The aim of this study was to assess the effect of 12 weeks of oral candoxatril (100 mg twice daily) in patients with chronic heart failure who were receiving conventional heart failure therapy including diuretic and ACE inhibitor treatment. The primary end-points were treadmill exercise performance, clinical signs and symptoms of heart failure, and quality of life scores. Secondary end-points were the assessment of safety and tolerability of candoxatril in this group of patients.
Methods
Sixteen centres within the United Kingdom participated in the study (see Appendix). The trial was conducted in accordance with the Declaration of Helsinki (1989) of the World Medical Association and with the approval of the local research ethics committees. The written informed consent of each subject was obtained prior to inclusion into the study.
Patients
The intention was to recruit 120 patients who were men or women of non-child bearing potential, aged between 21 and 75 years and were in established chronic heart failure of New York Heart Association (NYHA) Grade II or III. All patients were maintained on ACE inhibitor therapy at clinically relevant doses and were required to have a left ventricular ejection fraction of <45% and/or echocardiographic evidence of left ventricular impairment (shortening fraction of <20% or left ventricular end diastolic diameter of >5·5 cm). Exclusion criteria are detailed in Table 1 . Fig. 1 
Study protocol (see

)
In order to accommodate improved exercise times through a training effect, weekly exercise tolerance tests were performed for a minimum of 4 weeks during a single-blind placebo run-in phase. Each patient attended the clinic between 5 and 8 h after the morning dose of the study medication. A clinical examination, body weight measurement, treadmill exercise tolerance test and documentation of side effects and adverse events, were undertaken at each weekly visit. After week 3, if the last two consecutive exercise treadmill times were consistent i.e. within 15% and 60 s, then the patient entered the double-blind phase of the protocol. However, patients who did not fulfil this criteria remained on single-blind placebo therapy and the run-in-phase was extended to a maximum of 5 weeks. If after 5 weeks the criteria had not been met, the patient was withdrawn from the study.
Patients successfully completing the run-inphase, received a randomized, double-blind, allocation of either candoxatril 100 mg twice daily or matched placebo (Pfizer Limited, Sandwich, U.K.). Thereafter, patients underwent clinical and quality of life evaluation after 2, 4, 8 and 12 weeks with treadmill exercise tests performed every 4 weeks.
Exercise tolerance was measured using a treadmill exercise test following the S.T.E.E.P. protocol [26] . Clinical examination was used to assess symptoms and signs of heart failure. This included NYHA functional classification and assessment of ankle swelling using a visual analogue score. A 14-point quality of life questionnaire was completed by the patient once during the placebo run-in, and throughout the double-blind phase. This assessed symptoms of breathlessness (four questions), fatigue (four questions) and well being (six questions) on a seven-point graded scale. Chest radiographs were taken once during the placebo run-in phase and on completion of the study for measurement of cardiothoracic ratio. Regular monitoring of haematological, urinary and biochemical parameters were conducted throughout the study.
Statistical analyses
The first day of active therapy is defined as the baseline: 'day 0'. For each response variable, data were analysed as change from this baseline. All data were analysed using analysis of variance. 'A priori' covariates considered were centre, age, sex and aetiology of heart failure (ischaemic or non-ischaemic). These were all fitted in the model as either regression or categorical factors and 
Figure 1 Study design.
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both uncorrected means and adjusted least square means were calculated. Interactions with centre have not been fitted as there were too many small centres for this to provide a useful and practical interpretation.
Significance was taken at the 5% level. Results are presented as mean standard error of the mean or 95% confidence intervals expressed in parentheses.
Results
A total of 171 patients were screened, of whom 137 went on to receive single-blind placebo medication. Of these, 27 dropped out prior to randomization, 56 were randomized to receive candoxatril and 54 were randomized to receive placebo. A summary of the patient characteristics for the two groups is shown in Table 2 . Subjects were well matched in the two groups, but there was a slight excess of women in the candoxatril group (11 vs 4 in placebo group). The baseline mean total exercise time in the placebo group appeared to be 41 s longer than the candoxatril group but this was not statistically significant (P>0·10; unpaired t-test, placebo vs candoxatril).
Total exercise time
The duration and the relative improvement of exercise times in the two treatment groups are shown in Tables 3  and 4 . The change in exercise time compared to baseline across the 84 days of the study is shown in Fig. 2 . The overall improvement in exercise time on candoxatril in comparison to placebo (using adjusted least squares Range quoted in parentheses. There are no significant differences between the parameters. mean difference) was 34·1 s (95% confidence intervals: 5·1 to 63·0) which was statistically significant (P=0·02).
Quality of life and clinical status
The changes in the quality of life scores in the candoxatril group, when compared to the placebo group, showed no significant improvement: see Table 5 . Likewise, there were no significant differences in the improvement in NYHA class between the treatment groups: 7/56 improved on candoxatril and 11/54 on placebo. The cardiothoracic ratio, serum electrolytes, body weight, the severity of ankle oedema and cardiovascular examination were unchanged and demonstrated no significant differences between the groups. However, there was a trend for a modest reduction in blood pressure, both at rest and with exercise: see Table 6 .
Safety
The total number of patients suffering potentially serious adverse events on candoxatril was two compared with seven on placebo. Two further deaths occurred in the placebo group beyond 35 days after cessation of therapy. Total adverse events were similar in the two groups: 44/56 with candoxatril and 45/54 with placebo. Four patients in each group were considered to have adverse events, which, in the opinion of the investigator, might have been causally related to the study medication. There were three drug-related withdrawals in the candoxatril group and two in the placebo group.
Discussion
A previous study [24] has shown that in patients with mild to moderate chronic heart failure, candoxatril and captopril therapy produce a similar increase in exercise time following 84 days of treatment. This benefit of increased exercise capacity could result from a common and/or Adjusted mean change from baseline to day 84 in the candoxatril group compared to the placebo group. Adjusted mean change from baseline to day 84 in the candoxatril group compared to the placebo group. 
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distinct mechanism(s) of action. The current study has shown that in patients with mild chronic heart failure, combined candoxatril and ACE inhibitor therapy has a superior effect on exercise capacity than ACE inhibitor therapy alone. Therefore, neutral endopeptidase inhibition has a benefit over and above existing conventional therapy with ACE inhibition and suggests an additive effect via distinct mechanisms of action in accordance with the projected benefits of combined therapy [25] .
In agreement with previous studies [11] [12] [13] , candoxatril was well tolerated with no significant differences in adverse events between the two treatment groups. Moreover, the combination of candoxatril with ACE inhibitor therapy was not associated with significant detrimental effects.
Candoxatril was initially developed as a potential new anti-hypertensive agent. Preliminary work in healthy men showed a neutral [27] or even slight augmentation of blood pressure [10, 28] . In patients with essential hypertension, neutral endopeptidase inhibition has a very modest effect on reducing blood pressure [11, 14, 29] with the anti-hypertensive effect of atrial natriuretic peptide elevation potentially being offset by activation of the renin-angiotensin system [15] . However, combined neutral endopeptidase and ACE inhibition is a more efficacious and potent hypotensive regimen. This study suggests that compared to ACE inhibitor alone, combined ACE inhibitor and candoxatril therapy causes a modest reduction in blood pressure in patients with mild chronic heart failure.
Study limitations
The present study has some inherent limitations. Firstly, we have failed to show an effect of candoxatril on the quality of life, NYHA functional class or ankle oedema. However, the apparent lack of improvement in these parameters may reflect the insensitivity of the questionnaire, the low incidence of ankle oedema and the mild degree of heart failure in our study population (90% NYHA Grade II). Thus, the likelihood of the study being under powered and committing a type 2 error is high.
Secondly, there was a slight excess of women and a lower mean baseline exercise time in the candoxatril group. Because the study was fully randomized, these imbalances could only have occurred by chance. Indeed, the two groups were well matched in respect of age, concomitant therapy, baseline haemodynamic parameters, and type, duration and severity of heart failure. However, it has to be conceded that the disparity in baseline exercise times may mitigate against the positive finding of the study. Thus, the potential benefits demonstrated in the present study need to be confirmed in large scale randomised controlled trials.
Conclusions
This study has shown for the first time that candoxatril increases exercise capacity in patients with chronic heart failure who are maintained on ACE inhibitor therapy. It would, therefore, appear that candoxatril may provide a novel therapeutic adjunct to ACE inhibition in patients with chronic heart failure. These preliminary findings warrant further confirmation in large randomized controlled trials.
